期刊文献+

肾病综合征患者凝血分子标志物测定的临床价值 被引量:8

The value to detect the molecular markers in the patients with nephritic syndrome
下载PDF
导出
摘要 目的:观察45例原发性肾病综合征(N S)患者血浆止凝血分子标志物的变化,探讨其临床价值。方法:对照组25人,年龄(25.6±6.50)岁。患者组45人,年龄(29.87±10.87)岁。分别检测血浆血管性血友病因子(vW F)、D二聚体(D-D im er)、抗凝血酶Ⅲ(A TⅢ)、凝血酶原时间(PT)、活化部分凝血活酶时间(A PTT)及纤维蛋白原(FIB)含量。结果:(1)两组观察对象PT、A PTT无明显改变(P>0.05)。N S患者vW F、D-D im er、FIB均高于正常对照组(P<0.01),而A TⅢ明显低于正常对照(P<0.01)。(2)以血白蛋白(A IB)、24h尿蛋白(24H PR)、血胆固醇(C H)、血甘油三酯(TG)、血小板(PLT)为对象,观察止凝血指标与上述因素的相关性。结果显示vW F分别与C H、TG呈显著正相关(P<0.01及P<0.05)。A TⅢ与A IB呈显著正相关(P<0.01)而与24H PR呈显著负相关(P<0.01)。D二聚体与所有单因素之间无明确相关性。结论:vW F、A TⅢ、D二聚体分别从血管内皮细胞、抗凝、纤溶系统等不同角度反映了患者血液流变学状态,测定方法简便、性质稳定、结果可靠,是反映N S患者血栓前状态的良好指标。 Objective To study the changes of a series parameters of the hemorrheology coagulation and fibrinolytic system in the patients with nephritic syndrome. Method The lever of plasma vonwillebrand factor(vWF),D Dimer,antithrombin Ⅲ(ATⅢ),and prothrombin time(PT),activated partial thromboplestime(APTT),fibrinogen(Fbg) were measured in the 25 normal controls and 45 patients. We analysised the data with SPSS statistics software. Results (1)There were no significant differences in PT,APTT between both groups(P >0.05). The lever of vWF,D dimer,Fib was obviously higher but ATⅢwas obviously lower in patients than those in normal controls(P< 0.01). (2)vWF had positive correlation with cholesterol(CH),triglyceride(TG)(P< 0.01 and P< 0.05). ATⅢhad positive correlation with seroalbumin(P< 0.01) but had negative correlation with 24 hour proteins(P< 0.01). D Dimer had no correlation with each signal factor. Conclusion The lever of plasma vWF,ATⅢ,D Dimer reflected the blood hemodynamic state from the angles of the vascular endothelium,anticoagulation and fibrinolytic system separately. They were reliable and stable. So we think they may be regarded as the preferred index to show the prethrombotic state in the patients with nephritic syndrome.
出处 《实用医学杂志》 CAS 2005年第7期682-684,共3页 The Journal of Practical Medicine
  • 相关文献

参考文献8

  • 1祝怀平.血管性血友病因子的研究进展[J].国外医学(输血及血液学分册),2002,25(2):121-123. 被引量:8
  • 2李家增.弥散性血管内凝血——弥散性血管内凝血的病因和发病机制[J].中国实用内科杂志,2000,20(6):323-324. 被引量:8
  • 3Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranousnephropathy. Semi Nephrol,2003,23(4): 406-411.
  • 4Couser WG. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant, 1998,13(Suppl 1):10-15.
  • 5Frijns CJ, Derksen RH, De-Groot PG, et al. lupus anticoagulant and history of thrombosis are not associated withpersistent endothelial cell activation in systemic lupus erythematosus. Clin Exp Immunol, 2001,125(1): 149-154.
  • 6Atsumi T, Khamashta MA, Andujar C, et al. Elevated plasma lipoprotein(a) level and its association with impairedfibrinolysis in patients with antiphospholipid syndrome. J Rheumatology, 1998,25(1): 69-73.
  • 7Kim V, Spandorfer J. Epidemiology of venous thromboembolic disease. Emerg Med Clin North Am, 2001,19(4): 839-859.
  • 8Tkaczyk M,Owczarek D,Puczko-Nogal B,et al. Activation of coagulation cascade in children during an idiopathic nephrotic syndrome relapse,Pol Merkuriusz Lek,2000,8(46): 226-227.

二级参考文献1

共引文献14

同被引文献83

  • 1陈智彬,李梦帆,钟美慧,黄毅.下肢深静脉血栓形成发病机制研究[J].辽宁中医药大学学报,2020(8):143-146. 被引量:17
  • 2吴莉春,江峰,罗燕春.妊娠高血压综合征患者血浆纤维蛋白原测定的临床意义[J].中国误诊学杂志,2009,9(4):818-819. 被引量:11
  • 3王辰,翟振国.肺血栓栓塞症-深静脉血栓形成的预防策略[J].中国全科医学,2005,8(2):85-87. 被引量:38
  • 4王婷,桂保松.柠檬酸碳酸氢盐透析液安全性评估及其对淋巴细胞亚群的影响[J].中国血液净化,2007,6(4):199-201. 被引量:2
  • 5Kingston JK, BayVIY WM, Sellon DC,et al. Effects of sodium cit rate, low molecular weight heparin, and prostaglandin E1 on ag gregation, fibrinogen binding, and enumeration of equine platelets[J]. AM J Vet Res,2001,62(4) :547-554.
  • 6Ahmad S,Callan R,Cole J J,et al.Dialysate made from dry chemicals using citric acid increases dialysis dose[J].Am J Kidney Dis,2000,35(3):493-499.
  • 7Lehmann R, Schleiher E D. Molecular mechanism of diabetic nephropathy [ J]. Clin Chim Acta, 2000,297 ( 1 ) : 135.
  • 8Friedman A N, Hunsicker L G, Selhub J, et al. Clinical andnuitritional correlates of C-reactive protein in type 2 diabetic nephropathy [J]. Atherosclerosls, 2004,172( 1 ) : 121-125.
  • 9Yamada T, Sato A, Nishimori T. Importance of hyperc- oagulability over hyperglycemia for vascular complication in type 2 diabetes[J]. Diabetes Res Clin Pract,2000,49(1):13- 31.
  • 10Nation Kidney Foundation. KDOQI^TM clinical practice guideline and clinicalpractice recommendation for diabetes and chronic kidney disease[J]. Am J Kidney Dis,2007,49 (Suppl 2):S1- S180.

引证文献8

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部